Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q4 2016
|
OTIC |
|
Phase 3 Results |
Other |
None |
|
H2 2016
|
RDHL |
|
Phase 3 Results |
Other |
None |
|
H2 2016
|
RDHL |
|
Phase 3 Results |
Other |
Orphan Drug |
|
H2 2016
|
SAGE |
|
Phase 3 Results |
Respiratory |
Fast Track, Orphan Drug |
|
H2 2016
|
SNGX |
|
Phase 3 Results |
Oncology |
Fast Track, Orphan Drug |
|
H2 2016
|
NKTR-214 |
|
Phase 1/2 Results |
Oncology |
None |
|
Q4 2016
|
PBYI |
|
Phase 2 Results |
Oncology |
None |
|
Q4 2016
|
KPTI |
|
Phase 2/3 Results |
Oncology |
Orphan Drug |
|
H2 2016
|
ACRX |
|
NDA Submission |
Other |
None |
|
H2 2016
|
NVAX |
|
Phase 2 Results |
Infectious Disease |
Fast Track |
|